Cargando…

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab

PURPOSE: This first-in-human study was designed to evaluate the pharmacokinetic (PK) equivalence between HD204 and the European Union (EU)-sourced bevacizumab, between HD204 and the United States of America (US)-sourced bevacizumab, and between EU-sourced and US-sourced bevacizumab (NCT 03390673). M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Demarchi, Martin, Coliat, Pierre, Barthelemy, Philippe, Schott, Roland, BenAbdelghani, Meher, Kim, Michael, Hii, Jocelyn Chung Shii, Feyaerts, Peggy, Ang, Felicia Rui Xia, Derde, Marie Paule, Deforce, Filip, Petit, Thierry, Schwabe, Chris, Wynne, Chris, Park, Lisa Soyeon, Pivot, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460034/ https://www.ncbi.nlm.nih.gov/pubmed/34555031 http://dx.doi.org/10.1371/journal.pone.0248222

Ejemplares similares

TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU‐Herceptin(®) and US‐Herceptin(®) in healthy male subjects
por: Demarchi, Martin, et al.
Publicado: (2021)

Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev(®)), a bevacizumab biosimilar, under extended in-use conditions
por: Weiser, Sarah, et al.
Publicado: (2022)

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
por: Ingram, Rebecca L., et al.
Publicado: (2023)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
por: Cao, Di, et al.
Publicado: (2023)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Correction to: MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2022)

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial
por: Pivot, Xavier, et al.
Publicado: (2022)

Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting
por: Pivot, Xavier, et al.
Publicado: (2023)

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
por: Seo, Neungseon, et al.
Publicado: (2018)

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
por: Monk, Bradley J., et al.
Publicado: (2017)

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
por: Rosen, Lee S., et al.
Publicado: (2017)

The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
por: Goldschmidt, Jerome, et al.
Publicado: (2020)

Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes
por: Lashay, Alireza, et al.
Publicado: (2020)

Intraocular Injection of StivantⓇ (A Biosimilar to Bevacizumab): A Case Series
por: Mirshahi, Ahmad, et al.
Publicado: (2021)

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
por: Jin, Ran, et al.
Publicado: (2023)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
por: Calleja, Miguel Angel, et al.
Publicado: (2023)

A randomized, double‐blind, single‐dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab
por: Schwabe, C., et al.
Publicado: (2023)

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
por: Xiao, Xian, et al.
Publicado: (2022)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
por: Zhao, Zhiting, et al.
Publicado: (2023)

Biosimilars as a Future, Promising Solution for Financial Toxicity: A Review with Emphasis on Bevacizumab
por: Saleem, Tabinda, et al.
Publicado: (2020)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
por: Ratra, Dhanashree, et al.
Publicado: (2021)

Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab
por: Miguel‐Lillo, B., et al.
Publicado: (2023)

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
por: Li, Cheryl S. W., et al.
Publicado: (2019)

A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers
por: Sinn, Angela, et al.
Publicado: (2021)

Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey
por: Monk, Bradley J., et al.
Publicado: (2017)

In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma
por: Cardama, Georgina A., et al.
Publicado: (2023)

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab
por: Stroyakovskiy, Daniil L., et al.
Publicado: (2022)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Intravitreal bevacizumab
por: Khamar, Bakulesh M
Publicado: (2018)

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial
por: Verschraegen, Claire, et al.
Publicado: (2022)

A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers
por: Wang, Jin, et al.
Publicado: (2019)

A phase 1 study comparing the proposed biosimilar BS‐503a with bevacizumab in healthy male volunteers
por: Tajima, Naoyuki, et al.
Publicado: (2017)

Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US
por: Jin, Ran, et al.
Publicado: (2021)

Comparability strategy and demonstration for post-approval production cell line change of a bevacizumab biosimilar IBI305
por: Wu, Zhouyi, et al.
Publicado: (2023)

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
por: Trukhin, Dmytro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ogrdqaaie0ovmlevfb07rdd2cq